The Majority of Immunogenic Epitopes Generate CD4+ T Cells That Are Dependent on MHC Class II-Bound Peptide-Flanking Residues1

Peptides bind to MHC class II molecules with a defined periodicity such that the peptide-flanking residues (PFRs) P-1 and P11, which lie outside the core binding sequence (P1–P9), are solvent exposed and accessible to the TCR. Using a novel MHC class II:peptide binding assay, we defined the binding register for nine immunogenic epitopes to formally identify the flanking residues. Seven of the nine epitopes, restricted by H-2Ak, H-2Ag7, or H-2Ek, were found to generate T cells that were completely dependent on either P-1 or P11, with dependency on P-1 favored over P11. Such PFR dependency appears to be influenced by the type of amino acid exposed, in that residues that can form salt bridges or hydrogen bonds are favored over small or hydrophobic residues. Peptides containing alanine substitutions at P-1 or P11 in place of PFRs that mediate dependency were considerably less immunogenic and mediated a substantially reduced in vitro recall response to the native protein, inferring that PFR recognition increases immunogenicity. Our data suggest that PFR recognition is a common event characteristic of all MHC class II-restricted T cell responses. This key feature, which is not shared by MHC class I-restricted responses, may underlie the broad functional diversity displayed by MHC class II-restricted T cells.

[1]  N. Pavletich,et al.  Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.

[2]  E. Unanue,et al.  Identification of a major I-Ek-restricted determinant of hen egg lysozyme: limitations of lymph node proliferation studies in defining immunodominance and crypticity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Strominger,et al.  Minute quantities of a single immunodominant foreign epitope are presented as large nested sets by major histocompatibility complex class II molecules , 1993, European journal of immunology.

[4]  E. Unanue,et al.  Mechanisms and consequences of peptide selection by the I‐Ak class II molecule , 1999, Immunological reviews.

[5]  Partho Ghosh,et al.  The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3 , 1995, Nature.

[6]  C Oseroff,et al.  Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones , 1994, The Journal of experimental medicine.

[7]  D. Zaller,et al.  X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. , 1997, Immunity.

[8]  Bernhard Hemmer,et al.  Identification of High Potency Microbial and Self Ligands for a Human Autoreactive Class II–restricted T Cell Clone , 1997, The Journal of experimental medicine.

[9]  D. Wiley,et al.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 , 1993, Nature.

[10]  R. Mariuzza,et al.  Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. , 2000, Journal of molecular biology.

[11]  D. Wettstein,et al.  pH dependence and exchange of high and low responder peptides binding to a class II MHC molecule. , 1992, The EMBO journal.

[12]  J. Strominger,et al.  NOD background genes influence T cell responses to GAD 65 in HLA-DQ8 transgenic mice. , 1999, Human immunology.

[13]  A. Sette,et al.  Analysis of lysozyme‐specific immune responses by synthetic peptides. I. Characterization of antibody and T cell‐mediated responses to the N‐terminal peptide of hen egg‐white lysozyme , 1986, European journal of immunology.

[14]  J. Sidney,et al.  Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells. , 1991, Journal of immunology.

[15]  R. Tisch,et al.  Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice , 1993, Nature.

[16]  T. Leanderson,et al.  Clonal Selection in B‐Cell Growth and Differentiation , 1987, Immunological reviews.

[17]  L Gauthier,et al.  Kinetics of T-cell Receptor Binding by Bivalent HLA-DR·Peptide Complexes That Activate Antigen-specific Human T-cells* , 2000, The Journal of Biological Chemistry.

[18]  William S. Lane,et al.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.

[19]  A Sette,et al.  The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides , 1987, Science.

[20]  D. Wiley,et al.  Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. , 1998, Immunity.

[21]  D. Vignali,et al.  Immunoregulation of Th cells by naturally processed peptide antagonists. , 1999, Journal of immunology.

[22]  H. Grey,et al.  Structural requirements and biological significance of interactions between peptides and the major histocompatibility complex. , 1989, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[23]  R. Tisch,et al.  Determination of glutamic acid decarboxylase 65 peptides presented by the type I diabetes-associated HLA-DQ8 class II molecule identifies an immunogenic peptide motif. , 1999, Journal of immunology.

[24]  P. A. Peterson,et al.  Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. , 1998, Immunity.

[25]  E. Unanue,et al.  Identification of two distinct properties of class II major histocompatibility complex-associated peptides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Tobin,et al.  Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes , 1993, Nature.

[27]  A Sette,et al.  Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. , 1992, Science.

[28]  William Arbuthnot Sir Lane,et al.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles , 1993, The Journal of experimental medicine.

[29]  W. Taylor,et al.  A sequence pattern common to T cell epitopes. , 1988, The EMBO journal.

[30]  William Arbuthnot Sir Lane,et al.  Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. , 1999, Journal of immunology.

[31]  E. Sercarz,et al.  Modulation of the immunogenicity of antigenic determinants by their flanking residues. , 1998, Immunology today.

[32]  E. Unanue,et al.  Specificity of the T cell receptor: two different determinants are generated by the same peptide and the I-Ak molecule. , 1985, Journal of immunology.

[33]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[34]  W A Hendrickson,et al.  Crystal structure of I-Ak in complex with a dominant epitope of lysozyme. , 1998, Immunity.

[35]  D. Wiley,et al.  Peptide binding to HLA‐DR1: a peptide with most residues substituted to alanine retains MHC binding. , 1990, The EMBO journal.

[36]  E. Unanue,et al.  Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope , 1987, Nature.

[37]  D. Fremont,et al.  Structures of an MHC Class II Molecule with Covalently Bound Single Peptides , 1996, Science.

[38]  A Sette,et al.  T cell recognition of flanking residues of murine invariant chain-derived CLIP peptide bound to MHC class II. , 1998, Cellular immunology.

[39]  J. Strominger,et al.  Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor , 1994, The Journal of experimental medicine.

[40]  A. Smolyar,et al.  The crystal structure of a T cell receptor in complex with peptide and MHC class II. , 1999, Science.

[41]  D. Vignali,et al.  T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. , 1997, Immunity.

[42]  J. Strominger,et al.  The two membrane proximal domains of CD4 interact with the T cell receptor , 1996, The Journal of experimental medicine.

[43]  N. Shastri,et al.  The Choice of T‐Cell Epitopes Utilized on a Protein Antigen Depends on Multiple Factors Distant from, as well as at the Determinant Site , 1987, Immunological Reviews.

[44]  E. Unanue,et al.  Analysis of the interaction of peptide hen egg white lysozyme (34-45) with the I-Ak molecule. , 1989, Journal of immunology.

[45]  D. Wiley,et al.  Structure of a covalently stabilized complex of a human αβ T‐cell receptor, influenza HA peptide and MHC class II molecule, HLA‐DR1 , 2000, The EMBO journal.

[46]  A. Rudensky,et al.  Sequence analysis of peptides bound to MHC class II molecules , 1991, Nature.

[47]  E. Unanue,et al.  Antigenic competition at the level of peptide-Ia binding. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Maria V. Tejada-Simon,et al.  Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions1 , 2001, The Journal of Immunology.

[49]  K. Garcia,et al.  A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. , 2000, Science.

[50]  E. Unanue,et al.  A negatively charged anchor residue promotes high affinity binding to the MHC class II molecule I-Ak. , 1996, Journal of immunology.

[51]  A. Miller,et al.  Dominance and crypticity of T cell antigenic determinants. , 1993, Annual review of immunology.

[52]  E. Appella,et al.  Mechanisms influencing the immunodominance of T cell determinants , 1988, The Journal of experimental medicine.

[53]  Don C. Wiley,et al.  Crystal Structure of HLA-DR2 (DRA*0101, DRB1*1501) Complexed with a Peptide from Human Myelin Basic Protein , 1998, The Journal of experimental medicine.

[54]  A Sette,et al.  The Interaction between Protein‐Derived Immunogenic Peptides and Ia , 1987, Immunological reviews.

[55]  J. Rothbard Major histocompatibility complex-peptide interactions. , 1989, Current opinion in immunology.

[56]  H. Mcdevitt,et al.  The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  E. Unanue,et al.  Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule I-Ak. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Don C. Wiley,et al.  Structure of a human insulin peptide–HLA-DQ8 complex and susceptibility to type 1 diabetes , 2001, Nature Immunology.

[59]  E. Unanue,et al.  Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. , 2000, Immunity.